-
ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan
Friday, April 1, 2011 - 9:04am | 104ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has extended its drug discovery and development collaboration with Allergan, Inc. (NYSE: AGN). The collaboration is focused on the discovery of innovative new therapeutics for glaucoma and other ophthalmic indications and was...
-
Citi Reiterates Buy on Watson Pharmaceuticals (WPI)
Friday, April 1, 2011 - 9:00am | 99Citi is out with its report today on Watson Pharmaceuticals (NYSE: WPI), reiterating Buy. In a note to clients, Citi writes, "WPI expects to launch Nulecit (a generic of SNY's Ferrlecit for treating iron deficiency anemia in chronic dialysis patients) in a few weeks following GeneraMedix's ANDA...
-
Global Hunter Comments On Corcept's Corlux NDA Submission During Week Of April 11
Friday, April 1, 2011 - 8:56am | 123According to Global Hunter, Corcept Therapeutics (NASDAQ: CORT) announced its intent to submit an NDA for the use of CORLUX in Cushing's Syndrome to the FDA the week of April 11th, which is fairly in line with management's Q1:11 guidance and our expectations. Global Hunter reported that...
-
Benzinga's Top Upgrades (AGN, HBAN, CMCO, ALEX)
Friday, April 1, 2011 - 8:17am | 137Allergan Inc (NYSE: AGN) was upgraded by Leerink from "market perform" to "outperform." AGN's shares closed at $71.02 yesterday. Allergan's trailing-twelve-month operating margin is 25.41%. Jefferies upgraded Huntington Bancshares Incorporated (NASDAQ: HBAN) from “hold” to “buy.” HBAN's shares...
-
ULURU Inc. Reports Q4 EPS of $0.00
Friday, April 1, 2011 - 8:07am | 88ULURU Inc. (NYSE: ULU) today announced its financial results for the fourth quarter and year ended December 31, 2010. For the fourth quarter of 2010, the Company reported a net loss of $0.3 million, or $0.004 per share, compared with a net loss of $1.7 million, or $0.024 per share, for the same...
-
Benzinga's Top Pre-Market NASDAQ Gainers (HBAN, SHPGY, CSCO, AAPL)
Friday, April 1, 2011 - 8:06am | 114Huntington Bancshares Incorporated (NASDAQ: HBAN) rose 1.81% to $6.76 in the pre-market session. Analysts at Jefferies upgraded HBAN from “hold” to “buy.” Shire plc (NASDAQ: SHPGY) added 0.85% to $87.77 in the pre-market session. ORCL posted better-than-expected Q3 earnings. SHPGY's trailing-...
-
Piper Jaffray Comments On Corlux NDA Announcement (CORT)
Friday, April 1, 2011 - 7:27am | 284Corcept Therapeutics Inc. (NASDAQ: CORT) has announced plans to file their NDA for Corlux for the treatment of Cushing's syndrome during the week of April 11th, “in line with expectations,” Piper Jaffray reports. “The company plans to request a priority review, which could allow for a 4Q11 PDUFA....
-
Corcept Therapeutics Announces NDA Submission to Be Completed the Week of April 11
Thursday, March 31, 2011 - 4:29pm | 38Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it will submit its New Drug Application for the use of CORLUX in Cushing's Syndrome to the FDA the week of April 11, 2011.
-
Warner Chilcott PLC CFO Sells 15,406 Shares of WCRX
Thursday, March 31, 2011 - 4:28pm | 51In a Form 4 filed earlier today, Warner Chilcott PLC (NASDAQ: WCRX) CFO, Paul Herendeen, reported that he sold 15,406 shares of WCRX on March 30th for an average price of $23.25. The transaction totaled $358,190. Mr. Herendeen owns 371,715 direct shares of WCRX. Source: The Washington Service
-
Warner Chilcott PLC Officer Sells 18,020 Shares of WCRX
Thursday, March 31, 2011 - 4:25pm | 54In a Form 4 filed earlier today, Warner Chilcott PLC (NASDAQ: WCRX) Officer, Carl Reichel, reported that he sold 18,020 shares of WCRX on March 30th for an average price of $23.25. The transaction totaled $418,965. Mr. Reichel owns 371,594 direct shares and 143,016 indirect shares of WCRX....
-
Warner Chilcott PLC Vice-President Sells 16,848 Shares of WCRX
Thursday, March 31, 2011 - 4:23pm | 54In a Form 4 filed earlier today, Warner Chilcott PLC (NASDAQ: WCRX) Vice-President, Anthony Bruno, reported that he sold 16,848 shares of WCRX on March 30th for an average price of $23.25. The transaction totaled $391,716. Mr. Bruno owns 308,123 direct shares and 142,399 indirect shares of WCRX...
-
Crude on the Move
Thursday, March 31, 2011 - 4:21pm | 942Cusick's Corner Volume is way down, window dressing is done and the market rests in front of the Unemployment data tomorrow. Take the afternoon looking at sectors and stocks that you believe will grow in a sub 9% unemployment environment. Keep in mind that you will have to take into consideration...
-
Watson Announces Approval of Nulecit, the First Generic Alternative to Ferrlecit for the Treatment of Iron Deficiency Anemia
Thursday, March 31, 2011 - 1:56pm | 75Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it is initiating launch activities of Nulecit, following FDA approval of GeneraMedix Inc.'s, Abbreviated New Drug Application (ANDA). Nulecit is the first bioequivalent and therapeutically equivalent alternative to Sanofi-Aventis'...
-
Options Brief: Endo Pharmaceuticals Holdings (ENDP)
Thursday, March 31, 2011 - 11:30am | 99Shares of Endo Pharmaceuticals Holdings (NASDAQ: ENDP) are higher on the session by 0.18%, trading at $38.01. Overall put volume is now running at 5.77x the daily average, with 0% of all puts traded being purchases on the offer. 1,529 contracts have traded on the session so far. Endo...
-
Investigational Direct-Acting Antiviral BMS-790052 Plus PEG-Interferon Alfa and Ribavirin Achieved Up to 92% Sustained Virologic Response in Phase II Dose-Ranging Study
Thursday, March 31, 2011 - 10:32am | 129Bristol-Myers Squibb Company (NYSE: BMY) today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic...